- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Proteomics to Confirm Treatment Benefit in NSCLC
A proteomic test can predict outcome with chemotherapy versus erlotinib in NSCLC patients.
Italian study results confirm that a multivariate serum protein test predicts improved survival after treatment with chemotherapy versus erlotinib for non-small-cell lung cancer (NSCLC), but only among patients who are likely to have a poor outcome with the latter treatment type.
Specifically, patients predicted to have poor survival outcomes with epidermal growth factor receptor—tyrosine kinase inhibitors (EGFR–TKI) according to the proteomic test survived a median 3 months longer when treated with chemotherapy than their counterparts who received the EGFR–TKI erlotinib.
By contrast, neither treatment regimen was associated with superior overall survival among patients whose predicted outcomes were good.
Original report: http://bit.ly/1jugCqX
Source: medwire News
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
